BACKGROUND AND OBJECTIVES: FLT3 mutations are found in up to 30% of cases of acute myeloid leukemia (AML). Although new FLT3 mutations are being increasing by investigated, the role of FLT3 expression levels in wild type as well as in mutated FLT3 has only been infrequently addressed. DESIGN AND METHODS: To further evaluate the role of FLT3 in AML we investigated FLT3 expression levels in 207 adult AML patients and 8 healthy donors by real-time polymerase chain reaction (PCR). The expression levels were correlated with clinical parameters, FAB types, cytogenetics, flow cytometry, microarray analysis, FLT3 mutations, further molecular aberrations and prognosis. RESULTS: FLT3 expression levels were different in certain FAB types with increasing levels in the following order: M3<M3v<M6<M2<M4eo<M4<M0<M1<M5a<M5b. These results correlate with the FLT3 receptor surface expression (CD135) detected by flow cytometry (p<0.001), showing the highest CD135 expression in FAB M5. Independent analysis of FLT3 expression in cytogenetic AML subgroups showed the lowest levels in t(15;17) and the highest in the t(11q23) positive AML. In addition, FLT3 expression levels correlated with high percentages of bone marrow blasts (p<0.001) and high leukocyte counts (p<0.001). On the molecular level, no differences in FLT3 expression levels were detected between AML with and without any FLT3 mutation as well as for FAB M5 with or without MLL abnormalities (p=0.495). Furthermore, no significant difference could be found between the group of t(11q23) and MLL-PTD (p=0.180) or between MLL-PTD positive and MLL negative normal karyotypes (p=0.859). In patients with normal cytogenetics no impact or overall survival or event-free survival could be detected (p=0.128 and p=0.305, respectively) regardless of FLT3 muatation status, whereas investigating the group of patients with normal cytogenetics and wild-type FLT3, a clear tendency for a worse overall (p=0.059) and event free (p=0.087) survival was found. INTERPRETATION AND CONCLUSIONS: FLT3 expression levels are correlated with clinical data, genetic subgroups as well as prognosis. Furthermore, our data indicate that FLT3 expression and signaling are closely associated with FAB M5.
BACKGROUND AND OBJECTIVES:FLT3 mutations are found in up to 30% of cases of acute myeloid leukemia (AML). Although new FLT3 mutations are being increasing by investigated, the role of FLT3 expression levels in wild type as well as in mutated FLT3 has only been infrequently addressed. DESIGN AND METHODS: To further evaluate the role of FLT3 in AML we investigated FLT3 expression levels in 207 adult AMLpatients and 8 healthy donors by real-time polymerase chain reaction (PCR). The expression levels were correlated with clinical parameters, FAB types, cytogenetics, flow cytometry, microarray analysis, FLT3 mutations, further molecular aberrations and prognosis. RESULTS:FLT3 expression levels were different in certain FAB types with increasing levels in the following order: M3<M3v<M6<M2<M4eo<M4<M0<M1<M5a<M5b. These results correlate with the FLT3 receptor surface expression (CD135) detected by flow cytometry (p<0.001), showing the highest CD135 expression in FAB M5. Independent analysis of FLT3 expression in cytogenetic AML subgroups showed the lowest levels in t(15;17) and the highest in the t(11q23) positive AML. In addition, FLT3 expression levels correlated with high percentages of bone marrow blasts (p<0.001) and high leukocyte counts (p<0.001). On the molecular level, no differences in FLT3 expression levels were detected between AML with and without any FLT3 mutation as well as for FAB M5 with or without MLL abnormalities (p=0.495). Furthermore, no significant difference could be found between the group of t(11q23) and MLL-PTD (p=0.180) or between MLL-PTD positive and MLL negative normal karyotypes (p=0.859). In patients with normal cytogenetics no impact or overall survival or event-free survival could be detected (p=0.128 and p=0.305, respectively) regardless of FLT3 muatation status, whereas investigating the group of patients with normal cytogenetics and wild-type FLT3, a clear tendency for a worse overall (p=0.059) and event free (p=0.087) survival was found. INTERPRETATION AND CONCLUSIONS:FLT3 expression levels are correlated with clinical data, genetic subgroups as well as prognosis. Furthermore, our data indicate that FLT3 expression and signaling are closely associated with FAB M5.
Authors: T Kato; M Sakata-Yanagimoto; H Nishikii; M Ueno; Y Miyake; Y Yokoyama; Y Asabe; Y Kamada; H Muto; N Obara; K Suzukawa; Y Hasegawa; I Kitabayashi; K Uchida; A Hirao; H Yagita; R Kageyama; S Chiba Journal: Leukemia Date: 2014-09-19 Impact factor: 11.528
Authors: Katherine Tarlock; Todd A Alonzo; Michael R Loken; Robert B Gerbing; Rhonda E Ries; Richard Aplenc; Lillian Sung; Susana C Raimondi; Betsy A Hirsch; Samir B Kahwash; Amy McKenney; E Anders Kolb; Alan S Gamis; Soheil Meshinchi Journal: Clin Cancer Res Date: 2017-01-20 Impact factor: 12.531
Authors: Hyoung Jin Kang; Ji Won Lee; Sang Hyeok Kho; Min Jeong Kim; Young Jin Seo; Hyery Kim; Hee Young Shin; Hyo Seop Ahn Journal: J Korean Med Sci Date: 2010-05-24 Impact factor: 2.153
Authors: A Staffas; L S Arabanian; S Y Wei; A Jansson; S Ståhlman; P Johansson; L Fogelstrand; J Cammenga; F Kuchenbauer; L Palmqvist Journal: Oncogene Date: 2016-09-12 Impact factor: 9.867